Sun BioPharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sun BioPharma and buy or sell other stocks, ETFs, and their options commission-free!

About SNBP

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. 

CEO
Jennifer K. Simpson, PhD
CEOJennifer K. Simpson, PhD
Employees
Employees
Headquarters
Waconia, Minnesota
HeadquartersWaconia, Minnesota
Founded
2011
Founded2011
Employees
Employees

SNBP Key Statistics

Market cap
5.39M
Market cap5.39M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$1.11
52 Week high$1.11
52 Week low
$1.11
52 Week low$1.11

Stock Snapshot

With a market cap of 5.39M, Sun BioPharma(SNBP) trades at $4.00.

On 2026-03-15, Sun BioPharma(SNBP) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0.

Over the past 52 weeks, Sun BioPharma(SNBP) stock has traded between a high of $1.11 and a low of $1.11.

Over the past 52 weeks, Sun BioPharma(SNBP) stock has traded between a high of $1.11 and a low of $1.11.

People also own

Based on the portfolios of people who own SNBP. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.